> Details

Seraphin, Tobias P.; Joko-Fru, Walburga Y.; Manraj, Shyam S.; Chokunonga, Eric; Somdyala, Nontuthuzelo I. M.; Korir, Anne; N’Da, Guy; Finesse, Anne; Wabinga, Henry; Assefa, Mathewos; Gnangnon, Freddy; Hansen, Rolf; Buziba, Nathan G.; Liu, Biying; Kantelhardt, Eva J.; Parkin, Donald M.

Prostate cancer survival in sub-Saharan Africa by age, stage at diagnosis, and human development index: a population-based registry study

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Prostate cancer survival in sub-Saharan Africa by age, stage at diagnosis, and human development index: a population-based registry study
  • Contributor: Seraphin, Tobias P.; Joko-Fru, Walburga Y.; Manraj, Shyam S.; Chokunonga, Eric; Somdyala, Nontuthuzelo I. M.; Korir, Anne; N’Da, Guy; Finesse, Anne; Wabinga, Henry; Assefa, Mathewos; Gnangnon, Freddy; Hansen, Rolf; Buziba, Nathan G.; Liu, Biying; Kantelhardt, Eva J.; Parkin, Donald M.
  • Published: Springer Science and Business Media LLC, 2021
  • Published in: Cancer Causes & Control, 32 (2021) 9, Seite 1001-1019
  • Language: English
  • DOI: 10.1007/s10552-021-01453-x
  • ISSN: 0957-5243; 1573-7225
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Objectives</jats:title> <jats:p>To estimate observed and relative survival of prostate cancer patients in sub-Saharan Africa (SSA) and to examine the influence of age, stage at diagnosis and the Human Development Index (HDI).</jats:p> </jats:sec><jats:sec> <jats:title>Patients and methods</jats:title> <jats:p>In this comparative registry study, we selected a random sample of 1752 incident cases of malign prostatic neoplasm from 12 population-based cancer registries from 10 SSA countries, registered between 2005 and 2015. We analyzed the data using Kaplan-Meier and Ederer II methods to obtain outcome estimates and flexible Poisson regression modeling to calculate the excess hazards of death</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>For the 1406 patients included in the survival analyses, 763 deaths occurred during 3614 person-years of observation. Of patients with known stage, 45.2% had stage IV disease, 31.2% stage III and only 23.6% stage I and II. The 1 and 5-year relative survival for the entire cohort was 78.0% (75.4–80.7) and 60.0% (55.7–64.6), while varying between the registries. Late presentation was associated with increased excess hazards and a 0.1 increase in the HDI was associated with a 20% lower excess hazard of death, while for age at diagnosis no association was found.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>We found poor survival of SSA prostatic tumor patients, as well as high proportions of late stage presentation, which are associated with inferior outcome. This calls for investment in health-care systems and action regarding projects to raise awareness among the population to achieve earlier diagnosis and improve survival.</jats:p> </jats:sec>